The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2018A Global Search for People with a Rare, Inherited Form of Parkinson's Disease
Study Rationale:
Mutations, or changes, in the genes PRKN and PINK1 cause inherited Parkinson's disease (PD) that starts at an early age. This type of Parkinson's accounts for roughly 13 percent of... -
Target Advancement Program, 2018Causes, Mechanism and Consequences of an Energy Crisis in Striatal Nerve Endings
Study Rationale:
Two proteins, PINK1 and parkin, prevent cell death by breaking down damaged mitochondria, cell's energy generators. Mutations in the PINK1/PRKN genes - genetic changes that render... -
Target Advancement Program, 2018Neuroprotective Effects of NFE2L1 in Parkinson's Models
Study Rationale:
NFE2L1 is a protein that controls the expression of genes involved in the differentiation and survival of dopamine neurons. NFE2L1 levels are reduced in dopamine neurons in the brains... -
Therapeutic Pipeline Program, 2018Development of ALK4290 as a Novel Parkinson's Therapeutic
Study Rationale:
There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune... -
Target Advancement Program, 2018Searching for Cellular Changes Associated with PINK1 and PRKN Mutations
Study Rationale:
PINK1 and parkin are two proteins that work together to keep cells healthy by ridding them of damaged mitochondria, cells' powerhouses. Mutations (changes) in the PINK1 and PRKN genes... -
Target Advancement Program, 2018Validation of CD4 T Cell Dependent Neurotoxicity in an Alpha-Synuclein Model of Parkinson's Disease
Study Rationale:
Microglia, an immune cell in the brain, takes up unneccessary alpha-synuclein proteins and passes it on to the major histocompatibility complex (MHCII). This involves an interaction...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.